Clinical trial
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the…
NCT01960348 · Alnylam Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT01960348 |
|---|---|
| Title | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis |
| Official title | APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP) |
| Lead sponsor | Alnylam Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Transthyretin-Related |
| Intervention type | Drug |
| Interventions | patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl) |
| Enrollment | 225 |
| Start date | Nov 1, 2013 |
| Primary completion | Aug 1, 2017 |
| Completion | Aug 1, 2017 |
| First posted | Oct 10, 2013 |
| Last update posted | Apr 22, 2024 |
| Countries | Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, Malaysia, Mexico and 9 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: